REYVOW(R) (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study

Patients on REYVOW had 3.8-7.2 Times Greater Odds of Achieving Pain Freedom at 2 Hours Versus Placebo in At Least 2 out of 3 Attacks, Resulting in Significant Therapeutic Gains of 10-20% INDIANAPOLIS, Oct. 6, 2020 -- (Healthcare Sales &Marketing Networ... Biopharmaceuticals, Neurology Eli Lilly, REYVOW, lasmiditan, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Pérez Silguero D, Pérez Silguero MÁ, Pérez-Silguero Jiménez S, Encinas Pisa P Abstract The case concerns a 54-year-old woman, with a history of fibromyalgia and normal preoperative ocular and systemic study, who presented with a long-lasting disabling photophobia, after sequential bilateral cataract surgery without complications. Photophobia was accompanied by good uncorrected VA, with no pain or subjective eye discomfort, without migraine or indicators of psychic conflict. It was refractory to any prescribed treatment of the ocular surface, finally responding to oral ant...
Source: Archivos de la Sociedad Espanola de Oftalmologia - Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research
Conclusion ESP block combined with ropivacaine treatment effectively reduced early postoperative pain and improved recovery after hepatectomy.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
By Dr. Stephen A. Berger   Cynomolgus monkey, a known reservoir of the Monkeypox virus   WHAT IS MONKEYPOX? Monkeypox, as the name implies, is a disease of monkeys (unlike chickenpox – which has no relation to chickens). Although the condition is reported in a group of eleven African countries, the virus was first discovered in a laboratory in Denmark in 1958, when it was first isolated from cynomolgus monkeys. The signs and symptoms are similar to those of smallpox. Following a three-day prodrome of fever, headache, myalgia, and back pain, patients develop a papular rash in the face, extremities, and genit...
Source: GIDEON blog - Category: Databases & Libraries Authors: Tags: Epidemiology News Source Type: blogs
AbstractPurpose of ReviewThe goals of this review are two folds: (1) to describe the recent understandings on the roles of calcitonin gene-related peptide- α (CGRP) in bone homeostasis and the underlying mechanisms of related neuronal regulation and (2) to propose innovative CGRP-modulated approaches for enhancing bone regeneration in challenging bone disorders.Recent FindingsCGRP is predominantly produced by the densely distributed sensory neuronal fibers in bone, declining with age. Under mechanical and biochemical stimulations, CGRP releases and exerts either physiological or pathophysiological roles. CGRP at phys...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
AbstractIntroductionThe double-blind, phase 3 PREEMPT trials demonstrated the efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis evaluated the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and quality of life.MethodsPooled, 24-week data were used to determine percentages of patients meeting responder criteria for the change in headache days ( ≥ 50% reduction in headache-day frequency), Headache Impact Test (HIT-6; ≥ 5-point improvement), MSQ Role Function-Res...
Source: Pain and Therapy - Category: Anesthesiology Source Type: research
AbstractIntroductionThe phase 3 PREEMPT trials demonstrated efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. OnabotulinumtoxinA significantly reduced headache frequency from baseline vs. placebo at 24  weeks; however, this measure may not fully capture the benefits of treatment. We evaluated the impact of onabotulinumtoxinA on patient-reported outcomes according to headache responder status.MethodsA post hoc analysis pooled 24-week data from the placebo-controlled, randomized, double-blind treatment phases of the PREEMPT trials. Patients were stratified by random...
Source: Pain and Therapy - Category: Anesthesiology Source Type: research
Did an L5-S1 interlam on a seemingly normal 31 year old guy with a central disc at the same level. Calls almost a week later with complaints of severe positional headache not relieved by fluids, caffeine, Tylenol or Advil. Saw him yesterday, says headaches are intermittent but severe and only relieved by ice and laying down. Here are the pics. Doesn’t look like a wet tap at all, but can’t deny the complaints of spinal headache. To blood patch or not to blood patch. Explained to him in... Weird case
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
Conclusion: SLT is an effective and safe treatment modality for OHT, POAG, and PXG among Ethiopian patients either as a first-line treatment or as an adjunct to topical glaucoma treatment. PMID: 33014442 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Are you sad? Just be happy! Does this irritate you? In today’s show, Gabe and Lisa ponder whether happiness really is a choice — especially for people who struggle with mental illness. How do we measure happiness? And what is happiness inflation? Join us for an in-depth conversation on whether or not people can actually choose happiness. (Transcript Available Below) Please Subscribe to Our Show: And We Love Written Reviews!  About The Not Crazy podcast Hosts Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, Mental Illness is an A...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: General Happiness Mental Health and Wellness Not Crazy Podcast Source Type: blogs
ConclusionEptinezumab 100  mg or 300 mg administered IV at day 0 and repeated at week 12 provided sustained migraine preventive benefit over a full 24 weeks and demonstrated an acceptable safety profile in patients with chronic migraine.Trial (Identifier:NCT02974153). Registered November 23, 2016.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Brain | Headache | Marketing | Migraine | Neurology | Pain | Pharmaceuticals | Study